Welcome to our dedicated page for Organigram Global SEC filings (Ticker: OGI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Organigram Global Inc. filings document the disclosures of a Canadian cannabis company listed on Nasdaq and the TSX. Its Form 6-K reports furnish news releases, material change reports, shareholder meeting materials, proxy forms and other exhibits covering operating results, product announcements, material agreements and corporate events.
The company’s regulatory record includes disclosure about licensed cultivation and processing, adult-use cannabis brands, cannabinoid beverages, the FAST nanoemulsion technology platform, Health Canada regulation, capital-structure matters, shareholder voting, board and committee governance, and director and executive compensation practices.
Organigram Global Inc. reported Q2 Fiscal 2026 net revenue of $59,794, down 9% from Q2 Fiscal 2025 as recreational cannabis sales fell. Gross margin before fair value adjustments declined to 25% and adjusted EBITDA dropped to $870, reflecting weaker product mix and higher returns provisions. The quarter swung to a net loss of $921 versus prior-year net income of $42,456, driven mainly by smaller fair value gains on derivatives and a $5,800 impairment on its U.S. hemp-derived products business.
For the six months ended March 31, 2026, net revenue rose 14% to $123,332, with adjusted gross margin improving to 34% and net income at $19,048. Organigram closed the acquisition of German operator Sanity Group in April 2026 for upfront consideration of €107.3 million and updated Fiscal 2026 guidance, now projecting net revenue to exceed $350 million, with adjusted EBITDA and adjusted gross margin expected to surpass Fiscal 2025 levels and free cash flow around break even. The company highlights strong international expansion, including Germany and Australia, but faces regulatory headwinds for U.S. hemp-derived THC products and continues to remediate a material weakness in internal controls over financial reporting.
Organigram Global Inc. will release its second quarter fiscal 2026 results for the period ended March 31, 2026 on Tuesday, May 12, 2026, prior to market open. The company will hold a conference call that day at 8:00 a.m. Eastern Time, with advance registration required through online links.
Organigram describes itself as a leading Canadian cannabis company focused on high-quality products for adult consumers and international partnerships. It operates cultivation, processing, edibles and fulfillment facilities across multiple Canadian provinces and markets a portfolio of brands including Edison, SHRED, Big Bag O’ Buds and others.
Organigram Global Inc. saw its strategic investor BT DE Investments Inc., an affiliate of British American Tobacco, update its ownership position through an amended Schedule 13D. As of April 15, 2026, the investor beneficially owned 42,231,089 Common Shares, representing 29.9% of the outstanding Common Shares, plus 50,673,288 Class A preferred shares, all on a non-diluted basis.
The change reflects completion of Organigram’s acquisition of Sanity Group GmbH and a concurrent private placement. BT DE received Common and Preferred Shares as consideration for its Sanity stake and purchased additional Shares in a private placement, including via top-up rights. The Preferred Shares are non-voting, convertible into Common Shares subject to ownership caps. Under an updated investor rights agreement, the investor can nominate up to 30% of Organigram’s board and retains pre-emptive, top-up and registration rights as long as certain ownership thresholds are maintained.
Organigram Global Inc. has closed its previously announced acquisition of Germany-based Sanity Group, paying upfront consideration of €107.3 million, split between €78.0 million in cash and €29.3 million in shares. Sellers may receive up to an additional €113.8 million in earnout consideration tied to Sanity’s financial performance for the 12-month period ending April 1, 2027.
To help fund the deal, Organigram completed a private placement with British American Tobacco’s subsidiary for total gross proceeds of about C$65.2 million and secured new senior secured credit facilities of up to C$60 million, including a C$20 million term loan initially drawn. The transaction expands Organigram’s presence across key European cannabis markets and adds a new Sanity executive, Max Konrad Narr, to its board during the earnout period.
Organigram Global Inc. reported that shareholders overwhelmingly approved its planned acquisition of Sanity Group GmbH and a related private placement with a BAT subsidiary. The transaction resolution, which allows the indirect acquisition of all remaining Sanity shares and the issuance of up to 96,287,602 common shares, received 93% support from disinterested shareholders at the March 30, 2026 meeting.
The company describes the deal as financially accretive, noting that Sanity generated positive EBITDA in 2025 and will strengthen Organigram’s leadership in the global cannabis market, including a major presence in Germany. All ten director nominees were elected with roughly 98% support, PricewaterhouseCoopers LLP was reappointed as auditor with 97.1% support, and unallocated awards under the long‑term equity incentive plan were approved with 93.6% support. Closing of the Sanity transaction, expected in April 2026, remains subject to customary conditions, including completion of the private placement and senior secured credit facilities.
Organigram Global Inc. is advancing its proposed acquisition of German cannabis company Sanity Group GmbH after proxy advisor ISS recommended shareholders vote FOR the transaction resolution. ISS cited compelling strategic benefits, including greater scale, geographic diversification, stronger market presence, balance sheet and cash flow.
Under the agreement, Sanity shareholders will receive cash and Organigram shares with a deemed value of C$3.00 per share, representing a 71.4% premium to the closing TSX price on the last unaffected trading date. Total upfront consideration is €113.4 million, comprising €80.0 million in cash and €33.4 million in shares, plus potential earn-out payments of up to €113.8 million based on Sanity’s performance in the 12 months after closing.
The independent members of Organigram’s board unanimously support the deal and recommend shareholders vote FOR at the Annual General and Special Meeting on March 30, 2026, where routine items such as director elections, auditor appointment and equity plan approvals will also be considered.
Organigram Global Inc. has mailed and filed a management information circular for a March 30, 2026 annual and special meeting where shareholders will vote on acquiring Sanity Group GmbH and on a related financing. The proposed deal values the upfront purchase price at €113.4 million, split between €80.0 million in cash and €33.4 million in shares at $3.00 per share, a 71% premium to the prior TSX close of $1.75. Sellers may receive up to an additional €113.8 million in earnout payments tied to Sanity Group’s performance. A concurrent private placement with BAT for 23,924,430 shares at $3.00 per share is expected to raise C$65.2 million to fund the cash portion and transaction expenses. The board unanimously supports the transaction, citing Sanity Group’s rapid revenue growth and strong margins, as well as the strategic expansion into key European cannabis markets, subject to shareholder and regulatory approvals.
Organigram Global Inc. is asking shareholders to approve a major cross-border acquisition and related share issuances, including up to 96,287,602 Common Shares tied to its purchase of Germany-based Sanity Group GmbH and a related private placement of Class A Preferred Shares to BAT.
Sanity Group is a leading European cannabis operator whose revenue grew from about €9 million in 2023 to €60 million in 2025, while gross margin improved from roughly 15% to 47%. The deal would make Sanity a wholly owned subsidiary and give Organigram a scalable platform across key European markets anchored in Germany.
The transaction requires approval by disinterested shareholders under TSX rules and MI 61‑101, along with TSX and German foreign investment clearances, and is targeted to close in the second quarter of 2026. At the same meeting, investors will also vote on electing ten directors, appointing PricewaterhouseCoopers LLP as new auditor, and re‑approving unallocated awards under the 2020 Equity Incentive Plan.
Organigram Global Inc. is introducing SHRED Shotz, a compact 65 mL cannabis beverage under its SHRED brand, powered by its FAST™ nanoemulsion technology designed for a roughly 15-minute onset. Each bottle contains 10 mg of THC and will launch in Blue Razzberry and OG Lemonade flavours.
SHRED Shotz is intended to extend the SHRED brand, which generated over $200 million in retail sales in 2025, into shot-sized beverages aimed at convenience and faster-onset effects. The product is expected to be available in March in Ontario and Atlantic Canada, with additional provinces to follow.
Organigram Global Inc. plans a major European expansion by agreeing to acquire all remaining shares of Germany-based Sanity Group GmbH it does not already own. Sellers will receive €80.0 million in cash and €33.4 million in Organigram shares upfront, plus potential earnout payments of up to €20.0 million in cash and €93.8 million in additional shares based on Sanity’s first-year performance after closing.
Organigram arranged up to $60.0 million in senior secured credit facilities from ATB Financial and a C$65.2 million private placement with British American Tobacco to fund the cash portion of the purchase price and transaction costs. The deal is a related-party transaction that requires disinterested shareholder approval under Canadian securities rules and TSX requirements, with closing targeted for the second quarter of 2026, subject to regulatory and shareholder approvals.
Sanity Group reported rapid growth, with net revenue rising from €9 million in 2023 to €61 million in 2025 and gross margins improving from 14.5% to 47.2%. Organigram’s board, supported by a fairness opinion from BMO Capital Markets, unanimously (excluding BAT nominees) determined the transaction is in the company’s best interests.